ipamorelin clinical trial human growth hormone secretagogue safety Research: Selective GH ipamorelin clinical trial safety growth

Villardita C, Smirni P, Vecchio I

the compositions comprise at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 6 mg, at least about 7 mg, at least about 8 mg, at least about 9 mg, at least about 10 mg, at least about 11 mg, at least about 12 mg, at least about 13 mg, at least about 14 mg, at least about 15 mg, at least about 16 mg, at least about 17 mg, at least about 18 mg, at least about 19 mg, at least about 20 mg, at least about 21 mg, at least about 22 mg, at least about 23 mg, at least about 24 mg, at least about 25 mg, at least about 26 mg, at least about 27 mg, at least about 28 mg, at least about 29 mg, or at least about 30 mg of anti-acne ingredient (e.g., salicylic acid) per mL of composition

The therapy addresses age-related decline in growth hormone levels by encouraging natural growth hormone release in physiologic pulses

hTERT RPE-1 cells were cultured in DMEM/F-12 (containing L-glutamine, HEPES buffer and sodium bicarbonate, Sigma-Aldrich) supplemented with 10% (v/v) FBS (Thermo Fisher Scientific), 100 U ml 1 penicillin (Thermo Fisher Scientific), 100 g ml 1 streptomycin (Thermo Fisher Scientific) and 0.1 mg ml 1 hygromycin B (Roth)

To evaluate growth on solid media, in all cases -with the exception of the metE mutant, which only grew in the presence of B12 and, therefore, plating with and without B12 was performed from liquid cultures supplemented with B12- the liquid cultures grown without B12 were plated in solid 7H10-ADC plates supplemented with or without AdoCbl (10 g/mL) and/or L-Met (25 g/mL)